Skip to main content

Table 2 Best CNS Response According to mRECIST, RANO-BM, and iRANO-BM (n = 63)

From: Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

 

mRECIST

RANO-BM

iRANO-BM

Overall response rate

30.1% (19)

17.5% (11)

17.5% (11)

Disease control rate

65% (41)

74.7% (47)

81% (51)

CR

7.9% (5)

3.2% (2)

3.2% (2)

PR

22.2% (14)

14.3% (9)

14.3% (9)

SD

34.9% (22)

57.1% (36)

63.5% (40)

PD

34.9% (22)

25.4% (16)

19% (12)

  1. mRECIST, modified Response Evaluation Criteria in Solid Tumors; RANO-BM, Response Assessment in Neuro-Oncology for Brain Metastases; iRANO-BM, immunotherapy Response Assessment in Neuro-Oncology adjusted for Brain Metastases; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease